Britain and America have forged a important commercial pact that will guarantee zero levies on UK drug exports being sold in the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to increase expenditure on pharmaceuticals through the public health system. This pledge secures that duties on these vital exports will be held at zero for a duration of 36 months.
This development is in response to recent warnings to significantly raise tariffs on branded pharmaceutical products, with increases discussed as high as double the cost.
"This arrangement between the UK bolsters the international landscape for innovative medicines and brings much-needed equity to U.S.–U.K. drug exports," a statement declared.
Economic Significance
Pharmaceuticals are one of the Britain's largest goods shipped to the United States, which is easily the biggest market for major companies like GSK and AstraZeneca.
Trade data show that in the year leading up to last September, the UK sold medicines worth over eleven billion pounds to the US. This value represented a significant portion of total UK exports in that period.
"This deal safeguards employment, boosts funding and paves the way for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The pact entails several key pledges from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The sum drug companies must return to the NHS to stay within budget will be limited at fifteen percent. Last year, rebates were more than twenty percent.
Industry Background
This agreement takes place against a long-running row between the drug companies and the British authorities over drug pricing and NHS adoption.
The disagreement were intensified by arguments that American patients were paying significantly more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while substantial expansions have been pledged toward American operations.
The Science Minister publicly accepted that the NHS must increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
